Miyagi, Japan

Toshio Kudo

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Tohoku Techno Arch Co., Ltd.. Active years: 2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Toshio Kudo. Retrieved from https://idiyas.com/inventor/toshio-kudo-tzaj4xqd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Toshio Kudo

Introduction

Toshio Kudo is a prominent inventor based in Miyagi, Japan. He is known for his significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. His work focuses on creating innovative solutions that enhance therapeutic efficacy while minimizing costs.

Latest Patents

Kudo holds a patent for a diabody-type bispecific antibody. This invention is characterized by its low immunogenicity and high infiltrating activity into tumor tissues. The diabody-type bispecific antibody can be mass-produced at a low cost using microorganisms. It can also be easily altered in function through genetic engineering. This invention demonstrates remarkable effects compared to conventional bispecific antibodies, even at low concentrations and without the need for super antigens.

Career Highlights

Kudo is associated with Tohoku Techno Arch Co., Ltd., where he continues to advance his research and development efforts. His innovative approach has positioned him as a key figure in the biotechnology sector. He has made significant strides in improving the effectiveness of cancer therapies through his inventions.

Collaborations

Kudo has worked alongside notable colleagues such as Izumi Kumagai and Ryutaro Asano. Their collaborative efforts have contributed to the advancement of research in bispecific antibodies and related technologies.

Conclusion

Toshio Kudo's work in developing diabody-type bispecific antibodies showcases his commitment to innovation in biotechnology. His contributions have the potential to significantly impact cancer treatment and improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…